Summary

Eligibility
for people ages 1 month to 6 years (full criteria)
Location
at Oakland, California and other locations
Dates
study started
completion around
Principal Investigator
by Jennifer G. MichlitschElliot Stieglitz
Headshot of Jennifer G. Michlitsch
Jennifer G. Michlitsch
Headshot of Elliot Stieglitz
Elliot Stieglitz

Description

Summary

Official Title

A Phase 2 Study of Revumenib (SNDX-5613) in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia

Details

Keywords

Eligibility

Locations

  • UCSF Benioff Children's Hospital Oakland accepting new patients
    Oakland California 94609 United States
  • UCSF Medical Center-Mission Bay accepting new patients
    San Francisco California 94158 United States
  • Kaiser Permanente-Oakland accepting new patients
    Oakland California 94611 United States

Lead Scientists at UCSF

  • Jennifer G. Michlitsch
    Professor, Pediatrics, School of Medicine. Authored (or co-authored) 23 research publications
  • Elliot Stieglitz
    Juvenile myelomonocytic leukemia (JMML) is a blood cancer that affects young children and is difficult to diagnose. Currently available therapies cure only half of patients, with some children experiencing an aggressive disease course while some children get better with very little treatment. We have now shown that the presence of secondary mutations at diagnosis predicts a poor outcome.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Children's Oncology Group
ID
NCT05761171
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 78 study participants
Last Updated